drugset / Trial / NCT06265545
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
RandomizedFactorialOpen-labelTreatment
Summary
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
Timeline
- Start
- 2024-02-22
- Primary completion
- 2026-01-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gilteritinib | Small molecule | 120 mg | — |
| Subject | Ivosidenib | Small molecule | 500 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |
| Background | Selinexor | Other / unclassified | — | — |